Cerca Magnetics Secures €4.3M for Wearable Brain Imaging

Key Takeaways

1. Cerca Magnetics raised €4.3 million (~£3.8M / ~$4.75M) in a Series A round led by Guinness Ventures, at a €34.5 million post-money valuation
2. The UK startup has sold 19 systems across 12 countries and delivered over 100% annual sales growth for three consecutive years
3. Funding will go toward clinical approval in the UK and US, manufacturing scale-up, and international expansion into hospital settings
4. Cerca is backed by real-world clinical use cases including a £2.8 million UK Ministry of Defence contract and a pediatric autism research partnership with SickKids Toronto

Quick Recap

UK-based MedTech startup Cerca Magnetics has secured €4.3 million in a Series A funding round led by Guinness Ventures, as announced on April 23, 2026 via EU Startups.

The University of Nottingham spinout, founded in 2020, develops wearable brain imaging systems powered by quantum sensing technology and plans to use the capital to push its flagship OPM-MEG scanner through clinical approval pathways in the UK and the United States. The raise values the company at €34.5 million post-money.

Quantum Sensors and Wearable Neuroscience

Cerca Magnetics is built around magnetoencephalography (MEG), a technique that measures the faint magnetic fields generated by electrical activity in brain cells. What sets the company apart is its use of optically pumped magnetometers (OPMs), quantum sensors that operate at room temperature and replace the bulky, cryogenically cooled superconducting components found in traditional MEG machines.

The result is a lightweight, helmet-style wearable that lets patients move naturally during a scan, something that fixed clinical scanners fundamentally cannot enable. This mobility breakthrough unlocks a previously inaccessible patient group: infants and young children. The system adapts to different head sizes, meaning clinicians can scan adults and newborns using the same device.

Cerca’s current systems are deployed for conditions including epilepsy, multiple sclerosis, and dementia research. The clinical pipeline also includes a £2.8 million UK Ministry of Defence project building a mobile platform to assess blast-exposure effects on military personnel, and active research at SickKids Toronto studying autism spectrum conditions.

David Woolger, CEO and co-founder, described the investment’s purpose: “This investment enables us to move decisively into clinical applications, scaling our technology for routine use in hospitals in the UK and internationally. Our goal is to make advanced brain imaging more accessible, supporting earlier diagnosis and better treatment of neurological conditions.”

Inflection Point in the Market

The broader OPM-MEG market sits at a pivotal juncture. The global on-scalp optically pumped MEG sensors market was valued at $185 million in 2024 and is projected to reach $1.02 billion by 2033, growing at a CAGR of 21.1%. The helium-free MEG segment, which Cerca directly addresses, was estimated at $125.88 million in 2025 and is forecast to hit $355.42 million by 2032 at a 15.98% CAGR.

Traditional MEG systems require liquid helium cooling, which is expensive, logistically demanding, and architecturally limiting. The shift toward room-temperature OPM systems is not just a technical upgrade; it is a fundamental cost and access restructuring of clinical neuroimaging.

Regulatory tailwinds are also converging. Both the UK and the US are actively funding quantum sensing programs for healthcare applications, and Cerca’s existing UK Ministry of Defence contract signals government-level validation beyond the research community.

The NIH in the US has separately awarded multi-million dollar grants to OPM-MEG developers, confirming federal interest in this technology category. For Cerca, closing a Series A at this moment positions it ahead of the clinical approval window before hospital procurement cycles begin to standardise around next-generation wearable neuroimaging.

Competitive Landscape

OPM-MEG Market Players

Cerca’s two most directly comparable competitors in the wearable, OPM-based MEG space are FieldLine Medical (Boulder, Colorado) and Kernel (Los Angeles, California).

Strategic Analysis

Cerca leads on deployed commercial traction at an early-stage valuation, making it the most capital-efficient player with a clear path to hospital adoption. Kernel holds a commanding advantage in total funding and AI-driven biomarker development, but its pivot to fNIRS rather than MEG targets a different signal modality and clinical use case, reducing direct overlap.

FieldLine remains Cerca’s most technically similar competitor, with comparable OPM sensor systems and overlapping pediatric focus, but its funding pathway has relied more heavily on US government grants than private capital markets.

Sci-tech Today’s Takeaway

I will say it plainly: this raise is quietly significant in ways the headline number does not fully capture. In my experience covering MedTech funding rounds, the most telling signal is not the size of the cheque but the commercial momentum underneath it.

Nineteen systems sold across twelve countries with 100% annual sales growth for three years in a row, at a company that is only six years old, that is the kind of traction most Series A startups in hardware-heavy sectors would trade almost anything for.

I think this is a big deal because the clinical-grade brain imaging market is one of the last large pockets of medical diagnostics still locked behind six-figure infrastructure costs and inaccessible form factors. The fact that Cerca’s technology can image an infant’s brain, something no conventional MEG system can do, is not a niche feature, it is a structural expansion of the addressable market.

I generally find that the companies who win these categories are not the ones with the most capital early on, but the ones who figure out clinical utility before their competitors do. Cerca appears to be on that path.